secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001104659-23-088342
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics Q2 2023 net loss $31.5M; revenue $6.9M down from $23.0M
-------------------------------------------------------------------------

- Net loss of $31.5M ($0.58 per share) vs $4.2M ($0.08 per share) in Q2 2022.
- Total revenue $6.9M, down 70% YoY; Q2 2022 included $15M milestone.
- KORSUVA injection net sales $11.4M; collaborative revenue $5.4M; vial orders up 46% QoQ.
- Cash and marketable securities $101.7M at June 30, 2023, down from $156.7M at Dec 31, 2022.
- CMS proposed ESRD PPS rule includes additional funding for TDAPA products; final rule expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923088342/0001104659-23-088342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923088342/tm2322717d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer